Monitor for initiation of a larger randomized study in pancreatic cancer and for updates from the ongoing Phase 3 liver cancer trial and Phase 2b MASH trial, which are more advanced programs.
Price Chart
Executive Summary
Can-Fite BioPharma presented final Phase IIa data for namodenoson in advanced pancreatic cancer at ESMO 2026. The study met its primary safety endpoint with a favorable profile, and exploratory survival findings in heavily pretreated patients were encouraging but hypothesis-generating due to the small, single-arm, open-label design. The filing is a routine clinical data update with no new regulatory or financial catalysts.
Key Facts
- Phase IIa study of namodenoson in 20 patients with advanced pancreatic ductal adenocarcinoma met primary safety endpoint.
- Only five mild-to-moderate adverse events (Grade 1-2) considered related; no Grade ≥3 treatment-related events or serious adverse events.
- Exploratory analysis of eight third-line patients surviving >2 months showed median overall survival of 6.28 months and median progression-free survival of 2.27 months.
- One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months.
- Study is single-center, open-label, non-randomized; findings are hypothesis-generating and support evaluation in a larger randomized study.
- Namodenoson is also in a Phase 3 trial for advanced liver cancer and a Phase 2b trial for MASH.
Financial Impact
No financial data or revenue impact reported; company market cap is $6M with no disclosed revenue or profitability.
Risk Factors
- Early-stage, small, non-randomized study with hypothesis-generating results only; no guarantee of success in larger trials.
- Company has a history of losses and needs additional capital to fund operations, as noted in the filing's risk factors.
- No revenue or near-term commercialization path for namodenoson in pancreatic cancer.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-112266 |
| Document: ea0309623-6k_canfite.htm | 0001213900-26-112266 |
| Document: 0001213900-26-112266-index-headers.html | 0001213900-26-112266 |
| Document: 0001213900-26-112266-index.html | 0001213900-26-112266 |
| Document: 0001213900-26-112266.txt | 0001213900-26-112266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | — | $1.65 (−4.07%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.65 (+15.38%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.65 (+28.26%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.65 (−24.66%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.65 (−29.79%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.65 (+30.08%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.65 (−30.08%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.65 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers